Rethinking Ovarian Cancer Treatment: Is More Chemotherapy Always Better?
For years, the standard of care for patients with advanced high-grade epithelial ovarian cancer has been a delicate balancing act between surgery and chemotherapy. A common question has been whether extending neoadjuvant chemotherapy (NACT) before surgery—delaying the procedure until after six cycles rather than three—would yield better survival outcomes. New data from the phase 2 CHRONO trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, suggests that more may not necessarily be better.
What the CHRONO Trial Reveals
The CHRONO trial, a multicenter, open-label study, followed 209 patients with FIGO stage III to IVA ovarian cancer. Researchers compared two groups: those who underwent surgery after three cycles of NACT and those who received six cycles before their operation. The findings were clear: delaying surgery did not improve disease-free survival (DFS), overall survival (OS), or quality of life.
With a median follow-up of over 40 months, the DFS for the 6-cycle arm was 23.4 months compared to 20.2 months in the 3-cycle arm—a difference that failed to reach statistical significance. Notably, the study found that surgery-related grade 3 or 4 adverse events were actually more frequent in the delayed surgery group (13.2% vs 5.8%).
Did You Know?
The CHRONO trial investigators noted that the control group (the 3-cycle arm) performed better than originally anticipated. This “better-than-expected” outcome suggests that current standard-of-care protocols are already highly effective, making it increasingly difficult for experimental, more aggressive approaches to show a statistical edge.
The Shift Toward Precision Oncology
The results from CHRONO highlight a broader trend in oncology: the move away from “one-size-fits-all” aggressive treatments. As we look to the future, the focus is shifting toward identifying which patients truly benefit from extended chemotherapy versus those who might be better served by earlier surgical intervention.
Experts are now calling for a deeper dive into tumor biology and chemosensitivity. Rather than simply adding more cycles of chemotherapy, the next generation of clinical trials will likely focus on biomarkers that predict how a patient’s specific cancer will respond to treatment, allowing clinicians to tailor the timing of surgery to the individual patient.
Clinical Implications and Future Trends
The lack of superiority for the 6-cycle approach means that for many patients, earlier surgery remains a viable and safer path. By minimizing the duration of pre-operative chemotherapy, clinicians may reduce the risk of chemotherapy-related toxicities while maintaining excellent surgical outcomes.
Pro Tip: When discussing treatment plans, patients and caregivers should ask their oncology team about the specific rationale for the timing of surgery. Understanding the balance between tumor reduction and the patient’s overall health status is key to shared decision-making.
Frequently Asked Questions (FAQ)
Q: Does delaying surgery after 6 cycles of chemotherapy improve survival?
A: No. The CHRONO trial found no statistically significant improvement in disease-free or overall survival when surgery was delayed until after 6 cycles compared to 3 cycles.
Q: Were there more side effects with delayed surgery?
A: Yes. The study observed that surgery-related grade 3 or 4 adverse events were more frequent in the group that underwent delayed surgery (13.2% vs 5.8%).
Q: What is the current gold standard for advanced ovarian cancer?
A: Standard care typically involves a combination of platinum-based chemotherapy and surgical cytoreduction. The CHRONO data supports the continued use of interval surgery after 3 cycles of NACT for eligible patients.
What are your thoughts on the evolution of cancer treatment protocols? Have you or a loved one navigated the complexities of ovarian cancer care? Join the conversation in the comments below or subscribe to our newsletter for the latest updates in oncology research.
